Bank Of America Corp Finch Therapeutics Group, Inc. Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.34 - $0.56 $2,722 - $4,483	-8,007 Reduced 99.31%	56 $0
Q4 2022 Feb 10, 2023	SELL	$0.36 - $56.4 $62 - $9,757	-173 Reduced 2.1%	8,063 $3,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $51.3 $3,141 - $92,083	1,795 Added 27.87%	8,236 $14,000
Q2 2022 Aug 12, 2022	BUY	$1.91 - $5.11 $1,824 - $4,880	955 Added 17.41%	6,441 $18,000
Q1 2022 May 16, 2022	SELL	$5.02 - $10.47 $44,637 - $93,099	-8,892 Reduced 61.84%	5,486 $27,000
Q4 2021 Feb 08, 2022	BUY	$8.95 - $16.88 $104,885 - $197,816	11,719 Added 440.73%	14,378 $143,000
Q3 2021 Nov 15, 2021	BUY	$12.2 - $16.75 $6,722 - $9,229	551 Added 26.14%	2,659 $35,000
Q2 2021 Sep 13, 2021	BUY	$12.03 - $17.51 $25,359 - $36,911	2,108 New	2,108 $30,000

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $563M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.